5mg
RETATRUTIDE
GLP-1/GIP/Glucagon triple agonist
R 890
VIEW CART
For research purposes only. Not for human consumption.
MECHANISM
Triple agonist of GLP-1, GIP, and glucagon receptors. Modulates energy homeostasis, adipose tissue metabolism, and insulin sensitivity through complementary receptor pathways.
RESEARCH OVERVIEW
Phase 2 clinical trials demonstrated significant reductions in body weight and improvements in metabolic markers. Research suggests potential applications in metabolic longevity pathways.
Ref: Jastreboff et al., New England Journal of Medicine, 2023
